All patients
age >= 55 yr age >= 60 yr age >= 65 yr delta variant (B.1.617.2, Indian) elderly (typically over 65yr) immunodepression omicron variant BA.1 (B.1.1.529) omicron variant BA.2 VOC
first booster dose in COVID-19 prophylaxis (excluding children) - Summary of results Outcome TE 95% CI n k I2 ROB Pub. bias deathsdetailed results UKHSA report week 12 (24 March 2022), 2022 0.12 [0.06; 0.24]
0.12 [0.06 ; 0.24 ] UKHSA report week 12 (24 March 2022), 2022 1 0% NA not evaluable deaths (time to event analysis only)detailed results UKHSA report week 12 (24 March 2022), 2022 0.12 [0.06; 0.24]
0.12 [0.06 ; 0.24 ] UKHSA report week 12 (24 March 2022), 2022 1 0% NA not evaluable confirmed COVID (any severity)detailed results Accorsi, 2022 0.35 [0.32; 0.38]
England (Andrews), 2021 0.25 [0.14; 0.44]
Mattiuzzi, 2022 0.15 [0.14; 0.17]
Ontario (Buchan), 2022 0.63 [0.49; 0.80]
Southern California (Tseng) - omicron, 2022 0.38 [0.32; 0.44]
Tenforde, 2022 0.03 [0.01; 0.07]
Thompson -VISIOn Network (omicron), 2022 0.18 [0.16; 0.21]
0.23 [0.15 ; 0.35 ] Accorsi, 2022, England (Andrews), 2021, Mattiuzzi, 2022, Ontario (Buchan), 2022, Southern California (Tseng) - omicron, 2022, Tenforde, 2022, Thompson -VISIOn Network (omicron), 2022 7 98% 139,301 NA not evaluable hospitalizationdetailed results Lauring, 2022 0.14 [0.09; 0.22]
Mattiuzzi, 2022 0.15 [0.11; 0.20]
Sisonke 2 (booster), 2021 0.15 [0.05; 0.45]
Thompson -VISIOn Network (omicron), 2022 0.10 [0.05; 0.18]
UKHSA report week 12 (24 March 2022), 2022 0.17 [0.11; 0.25]
0.15 [0.12 ; 0.18 ] Lauring, 2022, Mattiuzzi, 2022, Sisonke 2 (booster), 2021, Thompson -VISIOn Network (omicron), 2022, UKHSA report week 12 (24 March 2022), 2022 5 0% 11,690 NA not evaluable symptomatic Covid-19detailed results Accorsi, 2022 0.35 [0.32; 0.38]
England (Andrews), 2021 0.25 [0.14; 0.44]
Kirsebom (UKHSA), 2022 0.30 [0.29; 0.31]
Thompson -VISIOn Network (omicron), 2022 0.18 [0.16; 0.21]
0.27 [0.21 ; 0.34 ] Accorsi, 2022, England (Andrews), 2021, Kirsebom (UKHSA), 2022, Thompson -VISIOn Network (omicron), 2022 4 95% 131,448 NA not evaluable ICU admissiondetailed results Mattiuzzi, 2022 0.07 [0.02; 0.25]
0.07 [0.02 ; 0.25 ] Mattiuzzi, 2022 1 0% NA not evaluable 0.0 2.0 1.0 relative treatment effect www.metaEvidence.org 2024-05-03 09:13 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
pathologies: 89
- treatments: 1088,1331,1330,1329,1344,1328,1327
- roots T: 290
